Colorectal Cancer Therapeutics: Global Markets

March 2019 | 124 pages | ID: C5EFD32B711EN
BCC Research

Abstracts

REPORT SCOPE:

This report is a business analysis that examines market trends for colorectal cancer therapeutics. The report includes sections on the following topics

• Current prevalence of colorectal cancer, trend analysis and factors influencing future incidence.
• Market analysis by treatment type, including annual incidence and trend analysis.
• Risk factors and other drivers that may impact the future incidence of colorectal cancer.
• Review of the major market opportunities by identifying specific high-growth and emerging market opportunities.
• Market share and information on key market players.
• Analysis and forecast of the revenues for colorectal cancer treatment for the global market, major market subsegments subdivided by geographic region and further, by selected country.
• Detailed review of the current products, their indications for all identified market segments.
• Profile of the individual market subsegments within the major market segments analyzed and the distinguishing features of each of the market subsegments.

This report captures colorectal cancer therapeutics market revenue for different regions by treatment type, i.e., chemotherapy, targeted therapy and immunotherapy used for treating the disease. A detailed colorectal cancer therapeutics market analysis covers the regions of North America, Europe, Asia-Pacific, and Rest of World.

Market values are provided using 2017 as base year, 2018 as estimated year, and 2023 as forecasted year. Estimated values used are based on manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

REPORT INCLUDES:

• 39 data tables and 18 additional tables
• Detailed overview of the colorectal cancer (CRC) therapeutics and corresponding global markets
• Country specific data and analysis for France, Germany, Italy, U.K., Spain, Russia, India, China, Japan, United States, Canada, Middle East and Africa
• Evaluation of market dynamics with a focus on increasing prevalence of colorectal cancer cases, technological advancements in radiology and chemotherapy, and increasing cancer prevention initiatives
• Coverage of some of the significant CRC tests including CT colonography, double-contrast barium enema, and biopsy test and their usability study and future growth potential
• A look into regulatory environment, new products launces and technological advancements, and current strategies within the market
• Company profiles of major manufacturers and suppliers of CRC therapeutic drugs, including Abbott Laboratories, Bayer Healthcare, GlaxoSmithKline, Merck & Co. Inc., Pfizer, Inc. and Sanofi S.A.

Contents

CHAPTER 1 INTRODUCTION

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst’s Credentials
BCC Custom Research
Related BCC Research Reports

CHAPTER 2 SUMMARY AND HIGHLIGHTS

CHAPTER 3 OVERVIEW AND BIOLOGY

Introduction
Market Definition and Overview
Incidence
Stages of Colorectal Cancer
Stage
Stage I
Stage II
Stage III
Stage IV
Standard Treatment Options for Stage IV and Recurrent Colon Cancer
Epidemiology of Colorectal Cancer
Etiology
Genetic Factors
Environmental Factors
Pathophysiology
Risk Factors
Inherited Syndromes
Symptoms
Metastasis
Diagnosis
Colonoscopy
Biopsy
Laboratory Tests
CT Scan
Magnetic Resonance Imaging (MRI)
Ultrasound
Others
Prognosis
Blockbuster Drugs
Avastin
Opdivo
Cetuximab (Erbitux)
End-Users
Hospitals
Cancer Research Laboratories
Primary Healthcare and Community Health Centers
Others

CHAPTER 4 COLORECTAL CANCER MARKET DYNAMICS

Market Drivers
Increasing Cancer Prevalence Rates
Increasing Geriatric Population
Outreach Programs Raise Cancer Awareness
Cancer and Treatment Technologies
Increasing Adoption of Combination and Targeted Therapies
Market Restraints
Drug Patent Expiries and Generic Drugs Emergence
High Costs of The Screening Associated with The Drugs
Lack of Awareness in Underdeveloped Countries

CHAPTER 5 PIPELINE ANALYSIS

Research and Development Overview
New Product Development
Phase I Clinical Trials
Phase II Clinical Trial
Phase III Clinical Trials
Impact on Market

CHAPTER 6 GLOBAL COLORECTAL CANCER THERAPEUTICS MARKET BREAKDOWN BY TREATMENT TYPE

Market Size and Forecast
Chemotherapy
Overview
Neoadjuvant Chemotherapy
Adjuvant Chemotherapy
Systemic Chemotherapy
Regional Chemotherapy
First-Line Chemotherapy and Targeted Therapy
Side Effects
Second-Line Chemotherapy
Treatment of Liver Metastasis
Market Size and Forecast
Immunotherapy
Overview
Side Effects
Market Size and Forecast
Targeted Therapy
Overview
Targeted Chemotherapy Agents
Monoclonal Antibody Therapy
Tyrosine Kinase Inhibitors (TKIs)
Side Effects
Market Size and Forecast
Conventional Treatment Options
Surgery

CHAPTER 7 GLOBAL COLORECTAL CANCER THERAPEUTICS MARKET BREAKDOWN BY REGION

Introduction
Market Size and Forecast
North America
Market Size and Forecast
U.S.
Canada
Mexico
Europe
Market Drivers
Market Restraints
Market Size and Forecast
Germany
U.K.
France
Italy
Spain
Rest of Europe
Asia-Pacific
Market Size and Forecast
Market Drivers
Market Restraints
Japan
India
China
Rest of Asia-Pacific
Rest of World
Market Size and Forecast

CHAPTER 8 REGULATORY AND REIMBURSEMENT STRUCTURE

Overview of Regulations
United States
Canada
Europe
Japan
China
Overview of Pricing and Reimbursement
United States
Europe
Japan

CHAPTER 9 COMPETITIVE LANDSCAPE AND KEY DEVELOPMENTS

Overview
Bristol-Meyers Squibb
Roche
Key Developments, 2017-2019
Mergers and Acquisitions
New Product Launch
Agreement, Collaboration and Partnerships

CHAPTER 10 COMPANY PROFILES

ABBVIE
ABBOTT LABORATORIES
AMGEN
ASTRAZENECA PLC
BAYER HEALTHCARE
BRISTOL-MYERS SQUIBB
ELI LILLY AND CO.
F HOFFMAN-LA ROCHE LTD.
GLAXOSMITHKLINE
JOHNSON & JOHNSON
MERCK & CO. INC.
NOVARTIS AG
PFIZER, INC.
SANOFI S.A.
TAKEDA PHARMACEUTICALS

CHAPTER 11 APPENDIX

Acronyms

List Of Tables

LIST OF TABLES

Summary Table: Global Colorectal Cancer Therapeutics Market, by Treatment Type, Through 2023
Table 1: U.S. Colorectal Cancer Incidence in Males and Females, 2017
Table 2: Stage II and Substages of Colorectal Cancer
Table 3: Stage III and Substages of Colorectal Cancer
Table 4: Stage IV and Substages of Colorectal Cancer
Table 5: Treatment Options for Stage IV and Recurrent Colon Cancer
Table 6: Avastin Drug Details
Table 7: Opdivo Drug Details
Table 8: Cetuximab (Erbitux) Drug Details
Table 9: Global Trends in Population Growth of People Aged 60 Years and Older, 1980-2020
Table 10: Colorectal Cancer Phase I Clinical Trials, October 2018
Table 11: Colorectal Cancer Phase II Clinical Trials, October 2018
Table 12: Colorectal Cancer Phase III Clinical Trials, October 2018
Table 13: Global Market for Colorectal Cancer Therapeutics, by Treatment Type, Through 2023
Table 14: Global Colorectal Cancer Chemotherapy Market, by Region, Through 2023
Table 15: Global Colorectal Cancer Immunotherapy Market, by Region, Through 2023
Table 16: FDA Approved Therapeutic Monoclonal Antibodies used to Treat Cancer, 1997-2017
Table 17: Approved Tyrosine Kinase Inhibitors (TKIs) Used to Treat Cancer
Table 18: Global Colorectal Cancer Targeted Therapy Market, by Region, Through 2023
Table 19: Global Colorectal Cancer Therapeutics Market, by Region, Through 2023
Table 20: North American Colorectal Cancer Therapeutics Market, by Treatment Type, Through 2023
Table 21: North American Colorectal Cancer Therapeutics Market, by Country, Through 2023
Table 22: U.S. Colorectal Cancer Incidence in Males and Females, by Cancer Site, 2017
Table 23: Canadian Colorectal Cancer Statistics, 2017
Table 24: Canadian Market Statistics
Table 25: Mexican Market Statistics
Table 26: European Colorectal Cancer Therapeutics Market, by Treatment Type, Through 2023
Table 27: European Colorectal Cancer Therapeutics Market, by Country, Through 2023
Table 28: Asia-Pacific Colorectal Cancer Therapeutics Market, by Treatment Type, Through 2023
Table 29: Asia-Pacific Colorectal Cancer Therapeutics Market, by Country, Through 2023
Table 30: Japanese Market Statistics
Table 31: Indian Market Statistics
Table 32: Chinese Market Statistics
Table 33: Rest of World Colorectal Cancer Therapeutics Market, by Treatment Type, Through 2023
Table 34: Global Colorectal Cancer Therapeutics Market, by Leading Players, 2017
Table 35: Amgen: Company Financials, 2015-2017
Table 36: AstraZeneca Plc: Company Net Revenue, 2015-2017
Table 37: AstraZeneca Plc: Company Financials, by Therapeutic Product Group, 2015-2017
Table 38: Bristol-Myers Squibb: Revenue Details, by Region, 2015-2017
Table 39: Bristol-Myers Squibb: Oncology Product Sales, 2015-2017
Table 40: Eli Lilly and Co.: Net Revenue, by Segment, 2015-2017
Table 41: Eli Lilly and Co.: Selected Product Sales, 2016 and 2017
Table 42: F. Hoffmann-La Roche Ltd.: Net Revenue, by Segment, 2015-2017
Table 43: F Hoffman-La Roche Ltd.: Pharmaceutical Division Oncology Product Sales, 2015-2017
Table 44: GlaxoSmithKline: Oncology Product Pipeline
Table 45: Johnson & Johnson: Company Financials, by Segment, 2015-2017
Table 46: Johnson & Johnson: Pharmaceutical Therapeutic Area Product Sales, 2015-2017
Table 47: Johnson & Johnson: Oncology Product Sales, 2015-2017
Table 48: Merck & Co., Inc.: Therapeutic Area Product Sales, 2015-2017
Table 49: Merck & Co., Inc.: Oncology Product Sales, 2015-2017
Table 50: Novartis AG: Company Financials, by Business Segment, 2015-2017
Table 51: Pfizer, Inc.: Company Financials, 2015-2017
Table 52: Pfizer, Inc.: Innovative Health (IH) Division Financials, 2015-2017
Table 53: Pfizer, Inc.: Innovative Health (IH) Division Oncology Product Sales, 2015-2017
Table 54: Sanofi S.A.: Company Financials, 2015-2017
Table 55: Sanofi S.A.: Oncology Product Sales, 2015-2017
Table 56: Acronyms Used in Colorectal Cancer Therapeutics

List Of Figures

LIST OF FIGURES

Summary Figure: Global Colorectal Cancer Therapeutics Market, by Treatment Type, 2017-2023
Figure 1: Age-Standardized(W) Incidence Rate of Colon Cancer in Males and Females, by Region, 2018
Figure 2: Age-Standardized(W) Incidence Rate of Rectum Cancer in Males and Females, by Region, 2018
Figure 3: Five-Year Survival Rates, by Colorectal Cancer Location
Figure 4: North American Colorectal Cancer Therapeutics Market, 2017-2023
Figure 5: U.S. Colorectal Cancer Therapeutics Market, 2017-2023
Figure 6: Canadian Colorectal Cancer Therapeutics Market, 2017-2023
Figure 7: Mexican Colorectal Cancer Therapeutics Market, 2017-2023
Figure 8: European Colorectal Cancer Therapeutics Market, 2017-2023
Figure 9: German Colorectal Cancer Therapeutics Market, 2017-2023
Figure 10: Age-Standardized Cancer Incidence Rates of Colorectal Cancer in Males and Females, by English Regions, 2016
Figure 11: U.K. Colorectal Cancer Therapeutics Market, 2017-2023
Figure 12: French Colorectal Cancer Therapeutics Market, 2017-2023
Figure 13: Italian Colorectal Cancer Therapeutics Market, 2017-2023
Figure 14: Spanish Colorectal Cancer Therapeutics Market, 2017-2023
Figure 15: Rest of European Colorectal Cancer Therapeutics Market, 2017-2023
Figure 16: Asia-Pacific Colorectal Cancer Therapeutics Market, 2017-2023
Figure 17: Japanese Colorectal Cancer Therapeutics Market, 2017-2023
Figure 18: Indian Colorectal Cancer Therapeutics Market, 2017-2023
Figure 19: Chinese Colorectal Cancer Therapeutics Market, 2017-2023
Figure 20: Rest of Asia-Pacific Colorectal Cancer Therapeutics Market, 2017-2023
Figure 21: Rest of World Colorectal Cancer Therapeutics Market, 2017-2023
Figure 22: Federal and Inter-Provincial Approval System for Cancer Drugs in Canada
Figure 23: Global Colorectal Cancer Therapeutics Market Share, by Leading Players, 2017